Top 20 Pharmaceutical Companies in India
Top 20 Pharma Companies in India represent the driving force behind the country’s booming pharmaceutical industry. Leading names like Sun Pharmaceutical, Dr. Reddy’s, Cipla, Divi’s Laboratories, Lupin, and rising brands like Steris Healthcare Pvt Ltd showcase strong revenue growth, global reach, and innovation in generic and specialty medicines. These companies are at the forefront of drug manufacturing, exports, and research, making India a global hub for affordable and quality healthcare solutions.
1. Sun Pharmaceutical Industries
FY25 Revenue: ₹52,041 crore, up 9% YoY
Highlights: India’s largest drugmaker with 8% market share, strong global specialty growth (20% of revenue) and US sales of US$1.92 billion
2. Dr. Reddy’s Laboratories
FY25/2025 Revenue: ~₹31,229 crore
Highlights: Nearly 47% of revenue comes from the US; strong Q4 profitability
3. Aurobindo Pharma
FY25 Revenue: ₹30,922 crore
Highlights: Large generics business with global portfolio; resilient across markets
4. Steris Healthcare Pvt Ltd
Revenue: ₹ ~₹110.68 crore+
Headquarters: Navi Mumbai
Highlights: Fast-growing specialty formulations producer; recently crossed ₹100 crore revenue and announced South India expansion with plans for IPO generation of ~800 jobs expresspharma.in
5. Cipla
FY25 Revenue: ₹26,982 crore
Highlights: Leading respiratory and HIV drugs, strong export footprint; 48% revenue from exports
6. Zydus Lifesciences
FY25 Revenue: ₹22,247 crore
Highlights: 46% revenue from the US market; diversified portfolio in chronic and respiratory therapies
7. Lupin
FY25 Revenue: ₹22,002 crore
Highlights: 37% revenue from the US; strong performance in respiratory and metabolic segment
8. Biocon
FY25 Revenue: ₹14,762 crore
Highlights: Leader in biosimilars; 44% revenue from U.S. biosimilars
9. Glenmark Pharmaceuticals
FY25 Revenue: ₹13,128 crore
Highlights: Active in specialty generics and biosimilars with strong global reach
10. Alkem Laboratories
FY25 Revenue: ₹12,757 crore
Highlights: High growth in domestic portfolio fueled by diversified prescriptions
11. Torrent Pharmaceuticals
FY25 Revenue: ₹11,302 crore
Highlights: Strong regional heart and CNS portfolio; top pharma stock by 5‑year CAGR
12. Mankind Pharma
FY25 Revenue: ₹9,326 crore
Highlights: Dominates domestic market in OTC and specialized prescription categories
13. Divi’s Laboratories
FY25 Revenue: ₹9,078 crore
Highlights: World’s top API maker; Q4 net profit of ₹667 crore, revenue grew 19% YoY
14. Piramal Enterprises
FY25 Revenue: ₹8,949 crore
Highlights: Pharma combined with financing and diagnostics; diversified conglomerate
15. IPCA Laboratories
FY25 Revenue: ₹8,726 crore
Highlights: Focused on domestic formulations and generics with global exports
16. Abbott India
Position: Leading multinational subsidiary; strong nutrition and diagnostics portfolio
17. Alembic Pharmaceuticals
Position: Strong in retroviral and niche therapeutic segments; Gujarat manufacturing hub
18. Emcure Pharmaceuticals
Profile: Growing generics exporter with expanding global markets
19. Natco Pharma
Profile: Specializes in oncology and niche generics; strong presence in cancer drug portfolio
20. Laurus Labs
Profile: Major API supplier to top generics companies; diversified into nutraceuticals and biotech
Sector Trends
Export-driven growth: US market represents ~30–50% of revenues for major players such as Sun Pharma, Dr. Reddy’s, Cipla and Lupin
API manufacturing strength: Companies like Divi’s and Laurus lead the growing API sector valued at US$11.8 billion
Comparative Revenue Snapshot (FY25)
Company | Revenue |
Sun Pharma | ₹525.8 billion (+8.4 %) |
Dr. Reddy’s | US $3.81 billion (~₹325 b) (+13.8 %) |
Cipla | ₹275.5 billion (+8 %) |
Torrent Pharma | ₹115.2 billion (+7.35 %) |
Aurobindo Pharma | ~₹317 billion |
Alkem Laboratories | ₹129.65 billion |
Alembic Pharmaceuticals | ₹31.3 billion (2017 figure) |
Steris Healthcare Pvt Ltd | ₹11,068 million (₹11.07 billion) |
